Ionis Pharmaceuticals (IONS) Stock Insights
$7.46B
Market Cap
-12.55
P/E
112.06
Forward P/E
49
Score
IONS price $44.90 +0.94 +2.14%
Stocklytics score rationale: value 60, quality 33, growth 53.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 372776000 | 514179000 | 599674000 | 1122599000 | 729264000 | 810456000 | 587367000 | 787647000 | 705138000 | 944000000 |
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy…
IONS fair value $13.01. Price $44.90. Price is 245% above fair value.
Above fair value, and more expensive than usual. A larger premium than on 61% of days in the past 5 years.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 260.21M. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 166.18M. Net debt 2.24B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Model uncertainty high for this stock
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-04 | — | -1.22 | — | 181.56M |
| 2026-07-29 | -0.69 | -1.09 | 268.00M | 189.10M |
| 2026-04-29 | -0.56 | -0.85 | 246.00M | 195.56M |
| 2026-02-25 | -1.41 | -1.24 | 203.00M | 156.07M |
| 2025-10-29 | -0.61 | -1.15 | 156.72M | 153.57M |
| 2025-07-30 | 0.86 | 0.27 | 452.05M | 131.75M |
| 2025-04-30 | -0.75 | -1.11 | 131.61M | 150.59M |
| 2025-02-19 | -0.66 | -1.09 | 226.58M | 131.14M |
| 2024-11-06 | -0.95 | -1.16 | 133.81M | 144.44M |
| 2024-08-01 | -0.45 | -0.92 | 225.25M | 150.07M |
| 2024-05-07 | -0.98 | -1.05 | 119.00M | 131.42M |
| 2024-02-21 | -0.06 | -0.83 | 324.50M | 174.76M |
| 2023-11-02 | -1.03 | -1.04 | 144.21M | 132.90M |
| 2023-08-09 | -0.60 | -0.90 | 188.41M | 138.83M |
| 2023-05-03 | -0.87 | -0.91 | 130.52M | 140.51M |
| 2023-02-22 | -0.37 | -1.06 | 151.89M | 160.13M |
| 2022-11-09 | -0.33 | -0.74 | 159.77M | 143.95M |
| 2022-08-09 | -0.74 | -0.62 | 133.79M | 140.54M |
| 2022-05-04 | -0.46 | -0.71 | 141.92M | 122.46M |
| 2022-02-24 | 1.41 | 0.28 | 440.01M | 275.55M |
| 2021-11-03 | -0.58 | -0.53 | 133.09M | 163.67M |
| 2021-08-04 | -0.57 | -0.60 | 125.75M | 126.00M |
| 2021-05-05 | -0.64 | -0.53 | 111.61M | 138.50M |
| 2021-02-24 | -2.44 | 0.24 | 290.28M | 274.45M |
| 2020-11-04 | -0.22 | -0.09 | 160.08M | 65.49M |
| 2020-08-05 | -0.23 | -0.28 | 145.54M | 177.18M |
| 2020-05-06 | -0.10 | -0.11 | 133.37M | 45.73M |
| 2020-02-26 | 1.41 | 0.93 | 493.68M | 358.69M |
| 2019-11-06 | 0.18 | -0.32 | 167.89M | 298.47M |
| 2019-08-07 | -0.01 | -0.27 | 163.81M | 4.42B |
| 2019-05-09 | 0.92 | 0.43 | 297.21M | 282.83M |
| 2019-02-27 | 2.42 | 0.40 | 192.12M | 4.35M |
| 2018-11-06 | -0.03 | -0.16 | 145.40M | 775.44M |
| 2018-08-07 | -0.05 | -0.02 | 117.75M | 36.54M |
| 2018-05-04 | -0.01 | -0.01 | 144.42M | 433.26M |
| 2018-02-27 | 0.02 | -0.08 | 172.30M | 86.15M |
| 2017-11-07 | -0.02 | -0.05 | 118.31M | 200.56M |
| 2017-08-08 | -0.09 | -0.04 | 112.27M | 96.67M |
| 2017-05-09 | 0.03 | -0.10 | 115.80M | 183.84M |
| 2017-02-28 | 0.24 | -0.12 | 160.35M | 91.63M |
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-16 | Devers Shannon L. | Sell | 1.36K | $43.54 | 59.08K |
| 2026-10-16 | Swayze Eric | Sell | 53 | $43.54 | 2.31K |
| 2026-10-15 | Devers Shannon L. | Sell | 2.82K | — | — |
| 2026-10-15 | Devers Shannon L. | Buy | 2.82K | — | — |
| 2026-10-15 | Swayze Eric | Sell | 125 | — | — |
| 2026-10-15 | Swayze Eric | Buy | 125 | — | — |
| 2026-08-31 | BENNETT C FRANK | Buy | 110 | $51.31 | 5.64K |
| 2026-08-31 | O'NEIL PATRICK R. | Buy | 63 | $51.31 | 3.23K |
| 2026-08-31 | Monia Brett P | Buy | 98 | $51.31 | 5.03K |
| 2026-08-31 | Birchler Brian | Buy | 58 | $51.31 | 2.98K |
| 2026-07-31 | Hayden Michael R | Buy | 5.00K | $51.60 | 258.00K |
| 2026-07-30 | Hayden Michael R | Buy | 15.00K | $53.38 | 800.70K |
| 2026-07-15 | Reikes Peter N | Buy | 3.40K | — | — |
| 2026-07-15 | HANTSON LUDWIG | Buy | 3.40K | — | — |
| 2026-07-15 | HERMAN JOAN E | Buy | 5.22K | — | — |
| 2026-07-15 | HERMAN JOAN E | Sell | 5.22K | — | — |
| 2026-07-15 | BERTHELSEN SPENCER R | Buy | 5.22K | — | — |
| 2026-07-15 | BERTHELSEN SPENCER R | Sell | 5.22K | — | — |
| 2026-07-07 | BENNETT C FRANK | Sell | 5.54K | $83.58 | 462.69K |
| 2026-07-07 | BENNETT C FRANK | Buy | 15.00K | $85.46 | 1.28M |
| 2026-07-07 | BENNETT C FRANK | Sell | 15.00K | $85.46 | 1.28M |
| 2026-07-07 | BENNETT C FRANK | Sell | 15.00K | $85.46 | 1.28M |
| 2026-07-07 | Diaz Allene M. | Buy | 10.11K | $47.11 | 476.33K |
| 2026-07-07 | Diaz Allene M. | Sell | 10.11K | $85.42 | 863.64K |
| 2026-07-07 | Diaz Allene M. | Sell | 10.11K | $47.11 | 476.33K |
| 2026-07-07 | Kordasiewicz Holly B. | Sell | 362 | $84.30 | 30.52K |
| 2026-07-01 | YANG MICHAEL J. | Buy | 2.30K | — | — |
| 2026-07-01 | YANG MICHAEL J. | Buy | 5.37K | $79.19 | 425.17K |
| 2026-07-01 | LOSCALZO JOSEPH | Buy | 2.30K | — | — |
| 2026-07-01 | LOSCALZO JOSEPH | Buy | 5.37K | $79.19 | 425.17K |
| 2026-07-01 | HERMAN JOAN E | Buy | 2.30K | — | — |
| 2026-07-01 | HERMAN JOAN E | Buy | 5.37K | $79.19 | 425.17K |
| 2026-07-01 | KLEIN JOSEPH III | Buy | 11.52K | $39.94 | 460.03K |
| 2026-07-01 | KLEIN JOSEPH III | Sell | 99 | $79.45 | 7.87K |
| 2026-07-01 | KLEIN JOSEPH III | Buy | 2.30K | — | — |
| 2026-07-01 | KLEIN JOSEPH III | Sell | 11.42K | $79.04 | 902.55K |
| 2026-07-01 | KLEIN JOSEPH III | Buy | 5.37K | $79.19 | 425.17K |
| 2026-07-01 | KLEIN JOSEPH III | Sell | 11.52K | $39.94 | 460.03K |
| 2026-07-01 | Hayden Michael R | Buy | 2.30K | — | — |
| 2026-07-01 | Hayden Michael R | Buy | 5.37K | $79.19 | 425.17K |
| 2026-07-01 | Diaz Allene M. | Buy | 2.30K | — | — |
| 2026-07-01 | Diaz Allene M. | Buy | 5.37K | $79.19 | 425.17K |
| 2026-07-01 | BERTHELSEN SPENCER R | Buy | 2.30K | — | — |
| 2026-07-01 | BERTHELSEN SPENCER R | Buy | 5.37K | $79.19 | 425.17K |
| 2026-06-26 | Baroldi Joseph | Buy | 1.77K | $32.60 | 57.67K |
| 2026-06-26 | Baroldi Joseph | Buy | 3.87K | $56.78 | 219.51K |
| 2026-06-26 | Baroldi Joseph | Sell | 5.63K | $80.16 | 451.70K |
| 2026-06-26 | Baroldi Joseph | Sell | 3.87K | $56.78 | 219.51K |
| 2026-06-26 | Baroldi Joseph | Sell | 1.77K | $32.60 | 57.67K |
| 2026-06-26 | O'NEIL PATRICK R. | Sell | 3.07K | $80.00 | 245.52K |
| 2026-06-26 | Schneider Eugene | Buy | 26.00K | $60.89 | 1.58M |
| 2026-06-26 | Schneider Eugene | Sell | 26.00K | $81.05 | 2.11M |
| 2026-06-26 | Schneider Eugene | Sell | 26.00K | $60.89 | 1.58M |
| 2026-06-26 | Monia Brett P | Buy | 50.00K | $56.78 | 2.84M |
| 2026-06-26 | Monia Brett P | Sell | 50.00K | $80.59 | 4.03M |
| 2026-06-26 | Monia Brett P | Sell | 50.00K | $56.78 | 2.84M |
| 2026-06-25 | Monia Brett P | Buy | 21.07K | $32.60 | 686.95K |
| 2026-06-25 | Monia Brett P | Sell | 21.07K | $78.49 | 1.65M |
| 2026-06-25 | Monia Brett P | Sell | 21.07K | $32.60 | 686.95K |
| 2026-06-25 | Swayze Eric | Sell | 10.60K | $79.18 | 839.49K |
| 2026-06-24 | Monia Brett P | Buy | 14.56K | $32.60 | 474.82K |
| 2026-06-24 | Monia Brett P | Sell | 14.56K | $78.41 | 1.14M |
| 2026-06-24 | Monia Brett P | Sell | 14.56K | $32.60 | 474.82K |
| 2026-06-15 | BERTHELSEN SPENCER R | Buy | 8.00K | $24.42 | 195.36K |
| 2026-06-15 | BERTHELSEN SPENCER R | Sell | 8.00K | $73.49 | 587.92K |
| 2026-06-15 | BERTHELSEN SPENCER R | Sell | 8.00K | $24.42 | 195.36K |
| 2026-06-12 | Kordasiewicz Holly B. | Buy | 19.89K | $56.78 | 1.13M |
| 2026-06-12 | Kordasiewicz Holly B. | Buy | 12.00K | $32.60 | 391.20K |
| 2026-06-12 | Kordasiewicz Holly B. | Buy | 21.00K | $60.89 | 1.28M |
| 2026-06-12 | Kordasiewicz Holly B. | Sell | 41.00K | $73.09 | 3.00M |
| 2026-06-12 | Kordasiewicz Holly B. | Buy | 7.95K | $60.89 | 484.14K |
| 2026-06-12 | Kordasiewicz Holly B. | Sell | 19.84K | $74.05 | 1.47M |
| 2026-06-12 | Kordasiewicz Holly B. | Sell | 7.95K | $60.89 | 484.14K |
| 2026-06-12 | Kordasiewicz Holly B. | Sell | 12.00K | $32.60 | 391.20K |
| 2026-06-12 | Kordasiewicz Holly B. | Sell | 19.89K | $56.78 | 1.13M |
| 2026-06-12 | Kordasiewicz Holly B. | Sell | 21.00K | $60.89 | 1.28M |
| 2026-06-04 | Reikes Peter N | Buy | 10.75K | $75.13 | 807.87K |
| 2026-06-04 | HANTSON LUDWIG | Buy | 10.75K | $75.13 | 807.87K |
| 2026-06-04 | Reikes Peter N | Other | 0 | — | — |
| 2026-06-04 | HANTSON LUDWIG | Other | 0 | — | — |
| 2026-06-01 | BERTHELSEN SPENCER R | Buy | 8.00K | $24.42 | 195.36K |
| 2026-06-01 | BERTHELSEN SPENCER R | Sell | 8.00K | $75.67 | 605.36K |
| 2026-06-01 | BERTHELSEN SPENCER R | Sell | 8.00K | $24.42 | 195.36K |
| 2026-05-14 | Monia Brett P | Buy | 3.22K | $32.60 | 104.97K |
| 2026-05-14 | Monia Brett P | Sell | 3.22K | $78.68 | 253.35K |
| 2026-05-14 | Monia Brett P | Sell | 3.22K | $32.60 | 104.97K |
| 2026-05-13 | Monia Brett P | Buy | 1.32K | $32.60 | 42.90K |
| 2026-05-13 | Monia Brett P | Sell | 1.32K | $78.01 | 102.67K |
| 2026-05-13 | Monia Brett P | Sell | 1.32K | $32.60 | 42.90K |
| 2026-05-04 | LOSCALZO JOSEPH | Buy | 16.00K | $64.80 | 1.04M |
| 2026-05-04 | LOSCALZO JOSEPH | Buy | 12.00K | $60.20 | 722.40K |
| 2026-05-04 | LOSCALZO JOSEPH | Buy | 16.00K | $42.88 | 686.08K |
| 2026-05-04 | LOSCALZO JOSEPH | Buy | 10.32K | $41.08 | 423.99K |
| 2026-05-04 | LOSCALZO JOSEPH | Buy | 12.00K | $40.05 | 480.60K |
| 2026-05-04 | LOSCALZO JOSEPH | Sell | 59.51K | $74.90 | 4.46M |
| 2026-05-04 | LOSCALZO JOSEPH | Buy | 10.97K | $38.06 | 417.44K |
| 2026-05-04 | LOSCALZO JOSEPH | Sell | 17.78K | $75.58 | 1.34M |
| 2026-05-04 | LOSCALZO JOSEPH | Sell | 10.97K | $38.06 | 417.44K |
| 2026-05-04 | LOSCALZO JOSEPH | Sell | 12.00K | $40.05 | 480.60K |
| 2026-05-04 | LOSCALZO JOSEPH | Sell | 10.32K | $41.08 | 423.99K |
Latest filed quarter: Q2 2026.
Institutions holding: 556, holders +29 vs prior quarter. Ownership 109.65%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| FMR LLC | 24.63M | 75.32K | +0.31% | 1.95B |
| CAPITAL WORLD INVESTORS | 21.67M | 482.86K | +2.28% | 1.72B |
| BLACKROCK, INC. | 10.70M | 262.18K | +2.51% | 848.77M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7.86M | 50.63K | +0.65% | 623.18M |
| WELLINGTON MANAGEMENT GROUP LLP | 7.65M | 1.26M | +19.71% | 606.68M |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.21M | 93.17K | +1.31% | 571.80M |
| TWO SIGMA INVESTMENTS, LP | 6.25M | 394.71K | +6.74% | 495.75M |
| ROYAL BANK OF CANADA | 6.18M | 2.38M | +62.62% | 490.21M |
| STATE STREET CORP | 4.33M | 339.28K | +8.49% | 343.71M |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 3.96M | -2.20M | -35.71% | 313.94M |
| GEODE CAPITAL MANAGEMENT, LLC | 3.58M | -400.31K | -10.05% | 294.75M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.18M | 159.25K | +5.26% | 252.50M |
| JPMORGAN CHASE & CO | 2.67M | 308.15K | +13.04% | 216.20M |
| ARTISAN PARTNERS LIMITED PARTNERSHIP | 2.64M | 581.72K | +28.26% | 209.33M |
| TWEEDY, BROWNE CO LLC | 2.28M | 4.69K | +0.21% | 180.81M |
| DEEP TRACK CAPITAL, LP | 2.20M | 250.00K | +12.82% | 174.44M |
| GOLDMAN SACHS GROUP INC | 2.11M | 410.10K | +24.13% | 167.30M |
| BAKER BROS. ADVISORS LP | 2.05M | 0 | 0.00% | 162.36M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.98M | 0 | 0.00% | 156.97M |
| AMERICAN CENTURY COMPANIES INC | 1.95M | 283.27K | +17.03% | 154.38M |
| FRANKLIN TEMPLETON INC | 1.62M | 48.35K | +3.07% | 128.72M |
| SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. | 1.61M | 1.61M | New | 127.26M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.61M | 21.79K | +1.38% | 127.26M |
| BARCLAYS PLC | 1.60M | 1.31M | +453.05% | 127.11M |
| PICTET ASSET MANAGEMENT HOLDING SA | 1.60M | 162.00K | +11.29% | 126.98M |
| Period | Value |
|---|---|
| FY2015 | Nusinersen: 40000000.0 |
| FY2016 | Akcea Therapeutics: 0.0 |
| FY2017 | Akcea Therapeutics: 0.0 |
| FY2018 | Commercial: 254922000.0, Licensing and Other Royalties: 14755000.0, Product: 2237000.0, Research and Development Revenue Under Collaborative Agreements: 344752000.0, SPINRAZA Royalties: 237930000.0 |
| FY2019 | Commercial: 352450000.0, Licensing and Other Royalties: 17205000.0, Product: 42253000.0, Research and Development Revenue Under Collaborative Agreements: 770149000.0, SPINRAZA Royalties: 292992000.0 |
| FY2020 | Commercial: 364699000.0, Licensing and Other Royalties: 8117000.0, Product: 69999000.0, Research and Development Revenue Under Collaborative Agreements: 364565000.0, Spinraza Royalties: 286583000.0 |
| FY2021 | Commercial: 342395000.0, Licensing and Other Royalties: 19119000.0, Research and Development Revenue Under Collaborative Agreements: 468061000.0, Spinraza Royalties: 267776000.0, TEGSEDI and WAYLIVRA: 55500000.0 |
| FY2022 | Collaborative Agreement Revenue: 207222000.0, Commercial: 303358000.0, Eplontersen Joint Development Revenue: 76787000.0, Licensing and Other Royalties: 30993000.0, Product: 30051000.0, Research and Development Revenue: 284009000.0, Spinraza Royalties: 242314000.0 |
| FY2023 | Collaborative Agreement Revenue: 352657000.0, Commercial: 308591000.0, Licensing and Other Royalties: 33299000.0, Other Commercial: 68212000.0, Product: 34913000.0, Research and Development Revenue: 479056000.0, SPINRAZA Royalties: 240379000.0 |
| FY2024 | Collaborative Agreement Revenue: 332647000.0, Commercial: 293076000.0, Other: 22590000.0, Other Commercial: 56779000.0, Product: 34189000.0, Research and Development Revenue: 412062000.0, SPINRAZA Royalties: 216090000.0 |
| FY2025 | Commercial Member: 435848000.0, Product: 115315000.0, Royalty: 285529000.0 |
Insights · Dividends · Forecast · Financials · Learn
$7.46B
Market Cap
-12.55
P/E
112.06
Forward P/E
49
Score